At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 126 enrolled
Drug / intervention
Aprepitant +1 moredrug
Likely dose
Aprepitant 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·interventional·Posted Jun 23, 2010·Updated May 8, 2019
In Brief
A Phase 2 clinical trial evaluating Aprepitant and Placebo for Gastroparesis. Completed, enrolled 126 participants across 8 sites.
Detailed Summary
The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with placebo in patients with symptoms of chronic nausea and vomiting of presumed gastric origin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroparesis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartApr 2013
Primary CompletionAug 2015
Study CompletionSep 2015
TodayJul 2026
First PostedJun 23, 2010
Enrollment StartApr 1, 2013
Primary CompletionAug 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.0 years ago
Interventions
Aprepitantdrug
Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
Placebodrug
Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks